Previous studies have shown that vitexin treatment leads to apoptosis, a reduction in mitochondrial membrane potential and Bcl-2 protein expression and elevated Caspase-3 and Caspase-9 protein expression in human non-small-cell lung cancer A549 cells and human leukemia K-562 cells [37, 42]. The gene discussed is CASP9; the disease is non-small cell lung carcinoma.